Drug therapy problems related to cardiovascular agents and associated factors among heart failure patients: a prospective observational study of a tertiary inpatient setting in Uganda
Background: Heart failure (HF) is a clinical syndrome that is treated with multiple medications, putting patients at risk of drug therapy problems (DTPs). DTPs are a great concern in health care due to their significant impact on morbidity, mortality, and higher costs associated with health care.
Aims: This study aimed to assess the prevalence and factors associated with DTPs related to cardiovascular agents among HF patients hospitalized at the Mbarara Regional Referral Hospital.
Methods: A prospective observational study was conducted among hospitalized HF patients from November 2021 to January 2022. A total of 118 patients diagnosed with HF were recruited. Patient file reviews and interviewer-administered questionnaires were used for data collection. Univariate and multivariate logistic regressions were employed to determine factors associated with the DTPs.
Result: A total of 118 HF patients with a median age of 43 years were included in this study. Among them, 57 participants experienced a total of 81 DTPs with a prevalence of 48.3%. “Dosage too high” was the most common DTP (23, 28.3%) followed by “needs additional drug therapy” (22, 27.2%). Hospitalized HF patients aged 60 years and above (adjusted odds ratio [AOR]: 4.1; 95% confidence interval [CI]: [1.5 – 10.3]; P = 0.012) and taking more than five medications during their hospital stay (AOR: 2.92; 95% CI: [1.5 – 7.6]; P = 0.029) were significantly associated with experiencing at least one DTP.
Conclusion: Almost half of the hospitalized HF patients experienced at least one DTP during their hospital stay. “Dosage too high” and “needs additional drug therapy” were the most common DTPs. Hospitalized HF patients with poly-pharmacy (taking more than five cardiovascular agents) and aged above 60 were more likely to have DTPs. It is noted that patient groups who are at risk require follow-ups to improve the treatment outcome, and incorporation of clinical pharmacy service could be part of the solution.
Relevance for Patients: This study identifies the factors associated with the development of DTP to facilitate the development and implementation of prevention strategies for the commonly identified DTPs.
[1] Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill Medical; 2014.
[2] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975. doi: 10.1002/ejhf.592
[3] Mastromarino V, Casenghi M, Testa M, Gabriele E, Coluccia R, Rubattu S, et al. Polypharmacy in Heart Failure Patients. Curr Heart Fail Rep 2014;11:212-9. doi: 10.1007/s11897-014-0186-8
[4] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J 2021;42:3599-726. doi: 10.1093/eurheartj/ehab368
[5] Fernandez-Llimos F, Tuneu L, Baena MI, GarciaDelgadoA, Faus MJ. Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems. Curr Pharm Des 2005;10: 3947-67. doi: 10.2174/1381612043382558
[6] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association. Circulation 2019;139:e56-528. doi: 10.1161/CIR.0000000000000659
[7] Yuyun MF, Sliwa K, Kengne AP, Olga A, Bukhman G. Cardiovascular Diseases in Sub-Saharan Africa Compared to High-Income Countries: An Epidemiological Perspective. Glob Heart 2020;15:15. doi: 10.5334/gh.403
[8] Agbor VN, Ntusi NA, Noubiap JJ. An Overview of Heart Failure in Low-And Middle-Income Countries. Cardiovasc Diagn Ther 2020;10:244-51. doi: 10.21037/CDT.2019.08.03
[9] Glezeva N, Gallagher J, Ledwidge M, O’Donoghue J, McDonald K, Chipolombwe J, et al. Heart Failure in Sub-Saharan Africa: Review of the Aetiology of Heart Failure and the Role of Point-of-care Biomarker Diagnostics. Trop Med Int Health 2015;20:581-8. doi: 10.1111/tmi.12461
[10] Picchio V, Cammisotto V, Pagano F, Carnevale R, Chimenti I. Heart Failure in Sub-Saharan Africa. In: Cell Interaction-Regulation of Immune Responses, Disease Development and Management Strategies. London: Intechopen; 2020. p. 1-15. Available from: https:// www.intechopen.com/books/advanced-biometrictechnologies/liveness-detection-in-biometrics [Last accessed on 2022 Oct 21].
[11] Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice: The Patient-centered Approach to Medication Management. New York: McGraw Hill Professional; 2012.
[12] Pharmaceutical Care Network Europe. Classification for Drug Related Problems Version 9.1. Netherlands: Pharmaceutical Care Network Europe Association; 2020. p. 1-10. Available from: https://www.pcne.org/upload/ files/334_pcne_classification_v9-0.pdf [Last accessed on 2022 Jun 11].
[13] Hohmann C, Eickhoff C, Klotz JM, Schulz M, Radziwill R. Development of a Classification System for Drug-Related Problems in the Hospital Setting (APSDoc) and Assessment of the Inter-Rater Reliability. J Clin Pharm Ther 2012;37:276-81.
[14] Flesch M, Erdmann E. The Problem of Polypharmacy in Heart Failure. Curr Cardiol Rep 2006;8(3):217-25.
[15] Viktil KK, Blix HS. The Impact of Clinical Pharmacists on Drug-Related Problems and Clinical Outcomes. Basic Clin Pharmacol Toxicol 2008;102:275-80. doi: 10.1111/j.1742-7843.2007.00206.x
[16] Yadesa TM, Kitutu FE, Deyno S, Ogwang PE, Tamukong R, Alele PE. Prevalence, Characteristics and Predicting Risk Factors of Adverse Drug Reactions among Hospitalized Older Adults: A Systematic Review and Meta-analysis. SAGE Open Med 2021;9:20503121211039099. doi:10.1177/20503121211039099
[17] Sztramko R, Chau V, Wong R. Adverse Drug Events and Associated Factors in Heart Failure Therapy among the Very Elderly. Can Geriatr J 2011;14:79-92. doi: 10.5770/cgj.v14i4.19
[18] Rushton CA, Strömberg A, Jaarsma T, Kadam UT. Multidrug and Optimal Heart Failure Therapy Prescribing in Older General Practice Populations: A Clinical Data Linkage Study. BMJ Open 2014;4:e003698. doi: 10.1136/bmjopen-2013-003698
[19] Urbina O, Ferrández O, Luque S, Grau S, Mojal S, Pellicer R, et al. Patient Risk Factors for Developing a Drug-related Problem in a Cardiology Ward. Ther Clin Risk Manag 2015;11:9-15. doi: 10.2147/TCRM.S71749
[20] Tegegne GT, Yimamm B, Yesuf EA. Drug Therapy Problems and Contributing Factors among Patients with Cardiovascular Diseases in Felege Hiwot Referral and Jimma University Specialized Hospital, Ethiopia. Indo Glob J Pharm Sci 2015;5:26-39. doi: 10.35652/igjps.2015.21
[21] Shareef J, Sandeep B, Shastry CS. Assessment of Drug Related Problems in Patients with Cardiovascular Diseases in a Tertiary Care Teaching Hospital. J Pharm Care 2014;2:70-6.
[22] Niquille A, Bugnon O. Relationship between DrugRelated Problems and Health Outcomes: A CrossSectional Study among Cardiovascular Patients. Pharm World Sci 2010;32:512-9. doi: 10.1007/s11096-010-9401-1
[23] Basger BJ, Moles RJ, Chen TF. Development of an Aggregated System for Classifying Causes of DrugRelated Problems. Ann Pharmacother 2015;49:405-18. doi: 10.1177/1060028014568008
[24] Maggioni AP. Epidemiology of Heart Failure in Europe. Heart Fail Clin 2015;11:625-35. doi: 10.1016/j.hfc.2015.07.015
[25] Wendie TF, Angamo MT. Drug-Therapy Problems and Predictors among Hospitalized Heart-Failure Patients: AProspective Observational Study. Drug Healthc Patient Saf 2020;12:281-91. doi: 10.2147/DHPS.S268923
[26] WHO. World Health Organisation. WHO Collaborating Centre for Drug Statistics Methodology; 2022. Available from: https://www.whocc.no/atc_ddd_index [Last accessed on 2021 May 18].
[27] Niriayo YL, Kumela K, Kassa TD, Angamo MT. Drug Therapy Problems and Contributing Factors in the Management of Heart Failure Patients in Jimma University Specialized Hospital, Southwest Ethiopia. PLoS One 2018;13:e0206120. doi: 10.1371/journal.pone.0206120
[28] Gizaw K, Dubale M. Drug Related Problems and Contributing Factors among adult Ambulatory Patients with Cardiovascular Diseases at Gebretsadik Shawo General Hospital, Bonga, South West Ethiopia. J Nat Sci Res 2017;7:9-16.
[29] Seid E, Engidawork E, Alebachew M, Mekonnen D, Berha AB. Evaluation of Drug Therapy Problems, Medication Adherence and Treatment Satisfaction among Heart Failure Patients on Follow-up at a Tertiary Care Hospital in Ethiopia. PLoS One 2020;15:e0237781. doi: 10.1371/journal.pone.0237781
[30] Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative Clinical Outcomes Associated with Drug-related Problems in Heart Failure (HF) Outpatients: Impact of a Pharmacist in a Multidisciplinary HF Clinic. J Card Fail 2011;17:217-23. doi: 10.1016/j.cardfail.2010.10.009
[31] Hsu WT, Shen LJ, Lee CM. Drug-Related Problems Vary with Medication Category and Treatment Duration in Taiwanese Heart Failure Outpatients Receiving Case Management. J Formos Med Assoc 2016;115:335-42. doi: 10.1016/j.jfma.2015.11.014
[32] Shwetha N, Pradhan A, Shabaraya AR, Niveditha TV, Jose C, Ambika V. Risk Factors for Developing Drug Related Problems in Patients with Cardiovascular Diseases. Int J Res Rev 2021;8:403-9.
[33] Tegegne GT, Yimam B, Yesuf EA, Gelaw BK, Defersha D. Drug Therapy Problems among Patients with Cardiovascular Diseases in Felege Hiwot Referral Hospital, North East, Ethiopia. Int J Pharm Teach Pract 2014;5:989-96.
[34] Mekonnen AB, Yesuf EA, Odegard PS, Wega SS. Implementing Ward based Clinical Pharmacy Services in an Ethiopian University Hospital. Pharm Pract (Granada) 2013;11:51-7. doi: 10.4321/s1886-36552013000100009
[35] Tsige AW, Yikna BB, Altaye MB. Drug-Related Problems among Ambulatory Heart Failure Patients on Follow-Up at Debre Berhan Comprehensive Specialized Hospital, Ethiopia. Ther Clin Risk Manag 2021;17:1165-75. doi: 10.2147/TCRM.S337256
[36] Shegena EA, Nigussie KA, Tamukong R, Lumori BA, Yadesa TM. Prevalence and Factors Associated with Adverse Drug Reactions among Heart Failure Patients Hospitalized at Mbarara Regional Referral Hospital, Uganda. BMC Cardiovasc Disord 2022;22:480. doi: 10.1186/s12872-022-02937-7
[37] Yadesa TM, Kitutu FE, Tamukong R, Alele PE. Prevalence, Incidence, and Characteristics of Adverse Drug Reactions among Older Adults Hospitalized at Mbarara Regional Referral Hospital, Uganda: A Prospective Cohort Study. Clin Interv Aging 2021;16:1705-21.
[38] Prot-Labarthe S, Di Paolo ER, Lavoie A, Quennery S, Bussières JF, Brion F, et al. Pediatric Drug-Related Problems: A Multicenter Study in Four French-Speaking Countries. Int J Clin Pharm 2013;35:251-9. doi: 10.1007/s11096-012-9740-1
[39] Abraham RR. Drug Related Problems and Reactive Pharmacist Interventions for Inpatients Receiving Cardiovascular Drugs. Int J Basic Med Sci Pharm 2013;3:42-8.
[40] Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al. Medication Therapy Management Interventions in Outpatient Settings: A Systematic Review and Meta-analysis. JAMA Intern Med 2015;175:76-87. doi: 10.1001/jamainternmed.2014.5841
[41] Wondesen A, Berha AB, Woldu M, Mekonnen D, Engidawork E. Impact of Medication Therapy Management Interventions on Drug Therapy Problems, Medication Adherence and Treatment Satisfaction among Ambulatory Heart Failure Patients at Tikur Anbessa Specialised Hospital, Addis Ababa, Ethiopia: A One-Group Pre-post Quasi-experimental Study. BMJ Open 2022;12:e054913. doi: 10.1136/bmjopen-2021-054913